Did you forget to switch IDs, JP? You were the one
Post# of 30028
Posted On: 01/18/2015 4:48:50 PM
Did you forget to switch IDs, JP? You were the one who brought up credibility, so let's keep on topic. You post under multiple IDs with levels of concern and enthusiasm all over the charts, and you want to discuss credibility? LMAO
If you're not JP, then how did you make your initial post less than 3 weeks ago where you were so enthusiastic, and yet now you have major concerns over dilution? The shares issued hasn't changed much over the intervening 3 weeks, so you're either trying to deceive readers here with your multiple identities, or SurfBandito is a moron who did little or no DD before investing in this company.
So which ID should we believe aligns with your true sentiment toward this investment? JPetro or SurfBandito? Why have 2 identities at all, particularly when they have demonstrated different sentiments about the company? And you feel I have credibility issues? Look in the mirror, man. Which message board identity do you see staring back? Maybe you can start another shareholder dialogue with YOURSELF.
I told you personally and posted here long ago that the dilution doesn't concern me at this stage of the company, and that it has nothing to do with my share position. Your concern over share dilution doesn't make it a valid concern for every shareholder, particularly when most of us understand there are not many funding options available for pre-revenue companies that continue to move forward to bring their products to market. Biotech is especially expensive in that regard. There's a lot more involved than designing a product and getting it manufactured and then generating revenue from sales. Perhaps you can outline the multitude of options available to the company that don't involve shares, and how this would reduce or eliminate the dilution we've seen. How would a potential lender provide funding to Amarantus when they have revenue, where it doesn't involve issuing the lender shares?
Quote:http://investorshangout.com/post/view?id=2505...z3PDBVCfFR
can someone help me - I just bought my first shares in Amarentus today and would like to know what can we expect to hear during the conference next month on limpro. I brought at 8.2 cents, so I'm down a little. However, a friend of mine from Santa Monica said this was a great company with awesome leadership, and and if I place an order early before Jan. 1, I will have a chance to catch the next big run. I hope he is right. Good luck everyone. I'm excited to be here.
Quote:http://investorshangout.com/post/view?id=2505460
who is JP. I think you may have mistaken me with someone else?
If you're not JP, then how did you make your initial post less than 3 weeks ago where you were so enthusiastic, and yet now you have major concerns over dilution? The shares issued hasn't changed much over the intervening 3 weeks, so you're either trying to deceive readers here with your multiple identities, or SurfBandito is a moron who did little or no DD before investing in this company.
So which ID should we believe aligns with your true sentiment toward this investment? JPetro or SurfBandito? Why have 2 identities at all, particularly when they have demonstrated different sentiments about the company? And you feel I have credibility issues? Look in the mirror, man. Which message board identity do you see staring back? Maybe you can start another shareholder dialogue with YOURSELF.
I told you personally and posted here long ago that the dilution doesn't concern me at this stage of the company, and that it has nothing to do with my share position. Your concern over share dilution doesn't make it a valid concern for every shareholder, particularly when most of us understand there are not many funding options available for pre-revenue companies that continue to move forward to bring their products to market. Biotech is especially expensive in that regard. There's a lot more involved than designing a product and getting it manufactured and then generating revenue from sales. Perhaps you can outline the multitude of options available to the company that don't involve shares, and how this would reduce or eliminate the dilution we've seen. How would a potential lender provide funding to Amarantus when they have revenue, where it doesn't involve issuing the lender shares?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼